307 related articles for article (PubMed ID: 37515128)
1. Recent Developments in Human Papillomavirus (HPV) Vaccinology.
Williamson AL
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515128
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
Mandic A
J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M; Dillner J
Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.
Li M; Zhao C; Zhao Y; Li J; Wei L
Front Immunol; 2023; 14():1112750. PubMed ID: 36993948
[TBL] [Abstract][Full Text] [Related]
8. [Human papillomavirus vaccines].
Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
[TBL] [Abstract][Full Text] [Related]
9. [Human papillomavirus nonavalent vaccine. Update 2017].
Bosch FX; Moreno D; Redondo E; Torné A
Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
[TBL] [Abstract][Full Text] [Related]
10. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
12. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
13. [Human papillomavirus vaccination. Consensus Conference in pediatric age].
Bartolozzi G; Bona G; Ciofi M; De Martino M; Di Pietro P; Duse M; Esposito S; Gasparini R; Mariani L; Marostica G; Paravati F; Plebani A; Principi N; Zuccotti GV; Tovo PA
Minerva Pediatr; 2007 Jun; 59(3):165-82. PubMed ID: 17519861
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
Eun BW; Bahar E; Xavier S; Kim H; Borys D
Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
[TBL] [Abstract][Full Text] [Related]
15. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
16. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
17. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
18. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
20. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
Poljak M; Šterbenc A; Lunar MM
Expert Rev Anti Infect Ther; 2017 Nov; 15(11):987-999. PubMed ID: 29027811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]